Friday, Jan 19 2018 | Time 15:23 Hrs(IST)
image
  • BJP will bounce back to power in Karnataka : S M Krishna
  • EC holds meeting on 'office of profit' case against 20 AAP MLAs, sends recommendations to Prez
  • WADA welcomes rejection of legal challenge to whereabouts rule
  • Lupin launches generic Vibra-Tab Tablet in the US
  • HDFC Bank Q3 net rises by 20'10 percent
  • ITC Q3 net rises by 16'78 percent
  • At 14, J&K’s Soham tops Fide rated player category
  • Night chill intensifies, day temp remains above normal in Kashmir
  • Prez to felicitate exceptional women achievers at Rashtrapati Bhawan tom
  • Pak fires heavily on forward BoPs, villages along IB, woman among 2 killed
  • Sugar rates steady in Kolhapur market today
  • Reference rate fixed at 63'7183 against USD
  • 3 injured in firing in Lucknow: Two abducted girls rescued
  • WADA welcomes rejection of legal challenge to whereabouts rule
  • JKNPP demands probe into 'illegal backdoor appointments' in Govt Depts
Science Technology Share

WHO advises Dengvaxia be used only in people previously infected with dengue

WHO advises Dengvaxia be used only in people previously infected with dengue

Kolkata, Dec 14 (UNI) Following a consultation of the Global Advisory Committee on Vaccine

Safety, the World Health Organization (WHO) finds that the dengue vaccine CYD-TDV, sold

under the brand name Dengvaxia, prevents disease in the majority of vaccine recipients but

it should not be administered to people who have not previously been infected with dengue

virus.

This recommendation is based on new evidence communicated by the vaccine’s

manufacturer (Sanofi Pasteur), indicating an increase in incidence of hospitalization and

severe illness in vaccinated children never infected with dengue.

The WHO Global Advisory Committee on Vaccine Safety considered the company’s new

results from clinical trial data analyses. Those studies indicate that increased risk of severe

dengue disease in people who have never been infected affects about 15 per cent of the

vaccinated individuals.

The magnitude of risk is in the order of about 4 out of every 1000 seronegative patients

vaccinated who developed severe dengue disease during five years of observation. The risk

of developing severe dengue disease in non-vaccinated individuals has been calculated as

1.7 per 1000 over the same period of observation.

By contrast, for the 85 per cent who have had dengue disease before immunization, there

is a reduction of 4 cases of severe dengue per 1 000 who are vaccinated.

The possibility of risk for seronegative people was raised by WHO and published in a

position paper in July 2016: “…vaccination may be ineffective or may theoretically even increase

the future risk of hospitalized or severe dengue illness in those who are seronegative at the time

of first vaccination regardless of age."

As this risk had at that time not been seen in the age groups for which the vaccine was

licensed, WHO issued a conditional recommendation, emphasizing the use of the vaccine

in populations having been previously infected with dengue virus.

To minimize illness for seronegative vaccinated people, WHO recommends enhancing

measures that reduce exposure to dengue infection among populations where the vaccine

has already been administered.

For vaccine recipients who present with clinical symptoms compatible with dengue virus

infection, access to medical care should be expedited to allow for proper evaluation,

identification, and management of severe forms of the disease.

Dengue is a mosquito-borne flavivirus disease that has spread to most tropical and many subtropical areas. The disease is caused by four closely related viruses. There is no specific

dengue treatment and prevention is mainly limited to vector control measures. A safe and

effective dengue vaccine would therefore represent a major advance in the control of the

disease.

CYD-TDV is a live attenuated tetravalent vaccine made using recombinant DNA technology

and is administered in three phases separated by six-month intervals. It became commercially available in 2016 and is currently licensed in 19 countries.

UNI BM SJC

More News

Science has to be people centric: Dr Harsh Vardhan

18 Jan 2018 | 1:08 PM

Hyderabad, Jan 18 (UNI) Union Minister for Science and Technology Harsh Vardhan has said that the Science has to be people centric and its benefits would deliver to the people.

 Sharesee more..
Greater efforts needed to meet international family planning goals

Greater efforts needed to meet international family planning goals

17 Jan 2018 | 12:32 PM

Kolkata, Jan 17 (UNI) Women and girls have a human right to choose whether and when to become pregnant.

 Sharesee more..
TN pioneer in organ transplants, other states should follow it : Venkaiah

TN pioneer in organ transplants, other states should follow it : Venkaiah

16 Jan 2018 | 5:13 PM

Chennai, Jan 16 (UNI) Observing that Tamil Nadu was a pioneering state in organ transplantation in the country, Vice President M Venkaiah Naidu on Tuesday said other states should emulate it in providing affording medical care to the people.

 Sharesee more..
Echinococcosis, a parasitic disease that occurs in two main forms in humans

Echinococcosis, a parasitic disease that occurs in two main forms in humans

13 Jan 2018 | 12:16 PM

Kolkata, Jan 13 (UNI) Echinococcosis is a parasitic disease that occurs in two main forms in humans: cystic echinococcosis (also known as hydatidosis) and alveolar echinococcosis, caused by the tapeworms Echinococcus granulosus and Echinococcus multilocularis, respectively.

 Sharesee more..
20 die of tobacco related diseases a day in Karnataka ; GATS-2 Survey

20 die of tobacco related diseases a day in Karnataka ; GATS-2 Survey

11 Jan 2018 | 3:02 PM

Bengaluru, Jan 11 (UNI) Atleast 20 people die in Karnataka every day due to tobacco related diseases with cancer being the main scourge, according to the latest Global Adult Tobacco Survey (GATS-2).

 Sharesee more..
image